Session Chair Profile
Ph.D., CSO, CEO & Chairman, Invivoscribe, Inc.
Jeffrey Miller, Ph.D. has two decades of experience with personalized molecular medicine®. He founded Invivoscribe® in 1995 without outside investment. The company is a highly profitable vertically integrated international network of six wholly-owned ISO13485 manufacturing and ISO15189 clinical testing companies. They are located in the U.S., Europe and Asia and operate under a single quality and regulatory system. The companies offer GMP test reagents, internationally harmonized clinical testing, and CRO services for stratification of patients for treatment and enrollment in clinical trials. Dr. Miller received his undergraduate degree in biochemistry from UCLA, and a combined Ph.D. in biochemistry & molecular biology from UCSB.
Session Abstract – PMWC 2017 Silicon Valley
Session Synopsis: The advancement of the field of Precision Medicine, including the “Moonshot” to cure cancer, along with a variety of proposals to share big data are promising. But these endeavors will prove frustratingly empty unless we recognize and address the shortcomings of current diagnostic tests and the generation of “big data”. Further, money drives success and reimbursement depends on demonstrating that biomarker tests provide clear clinical value. This value proposition will lag unless we embrace standards, which exist but are not being embraced by the international community. This session will show how design-controlled development and validation of internationally harmonized biomarker assays will prove critical to achieving the promise of precision medicine.